Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of faecal bifidobacteria in preterm infants

G Boehm, M Lidestri, P Casetta, J Jelinek, F Negretti, B Stahl, A Marini

Background: The establishment of a balanced intestinal microflora which may protect against infection is desirable for the preterm infant.

Objective: To investigate the effect of a preterm formula milk supplement consisting of oligosaccharides in similar proportions to human milk on the faecal flora and stool characteristics of preterm infants.

Study design: To resemble the effect of human milk, an oligosaccharide mixture consisting of 90% galacto-oligosaccharides and 10% fructo-oligosaccharides was used to supplement a standard preterm formula at a concentration of 10 g/l. This supplemented formula was studied in 15 preterm infants, and the results were compared with those found in 15 infants fed a formula supplemented with maltodextrin as placebo. A group fed fortified mother’s milk was investigated as a reference group (n = 12). On four days during a 28 day feeding period (1, 7, 14, and 28), the faecal flora was investigated, and stool characteristics, growth, and possible side effects were recorded.

Results: During the study period, the number of bifidobacteria in the group fed the oligosaccharide supplemented formula increased to the upper range of bifidobacteria counts in the reference group. The difference between the supplemented and non-supplemented groups was highly significant (p = 0.0008). The stool characteristics were also influenced by the supplement: the stool frequency after 28 days was significantly lower in the control group than in the oligosaccharide supplemented group (p = 0.0079) and the reference group (p < 0.0001). Over the study period, the stool consistency in the control group became harder, but remained fairly stable in the other two groups. There was no effect of the different diets on the incidence of side effects (crying, regurgitation, vomiting) or on weight gain or length gain.

Conclusion: Supplementing preterm formula with a mixture of galacto- and fructo-oligosaccharides at a concentration of 10 g/l stimulates the growth of bifidobacteria in the intestine and results in stool characteristics similar to those found in preterm infants fed human milk. Therefore prebiotic mixtures such as the one studied may help to improve intestinal tolerance to enteral feeding in preterm infants.

In the neonatal period, the intestine is colonised in a stepwise process that depends on mode of delivery, environmental factors, bacterial interactions, and the host itself, resulting in colonisation with a complex heterogeneous bacterial flora.

Only a few studies have focused on the early establishment of a balanced intestinal flora in preterm infants, and they have shown delayed colonisation with bifidobacteria in preterm infants compared with full term infants. The data also indicate that the influence of prematurity of the intestine of preterm infants is not as important as the influence of extrinsic factors such as type of feeding, antibiotic treatment, and the nosocomial environment of these infants during intensive care.

Preterm infants are particularly vulnerable to intestinal infections, therefore the establishment of a balanced microflora that may protect against infection is desirable in such infants.

One extrinsic factor that is important for the timing and quality of intestinal colonisation is feeding. Breast milk seems to favour a more diverse microflora with dominance of bifidobacteria and/or lactobacilli, but the mechanism by which this occurs remains to be clarified. However, the neutral oligosaccharides of human milk have been identified as such prebiotic factors. It was recently shown that human milk oligosaccharides are resistant to enzymatic digestion in the upper gastrointestinal tract, which is a prerequisite for a prebiotic effect.

The composition of neutral oligosaccharides in human milk is very complex, and the functional consequences of these different structures are not fully understood.

In this study, we aimed to reproduce the prebiotic effect of human milk oligosaccharides. Because of the high amount of galactose in human milk oligosaccharides, we used available galacto-oligosaccharides derived from lactose as one component of the mixture. The second component was fructo-oligosaccharides extracted from chicory roots with a reduced amount of the low molecular mass fraction (degree of polymerisation (DP) > 10). Fructo-oligosaccharides with DP > 10, as a high molecular mass inulin fraction, have a slower fermentation rate than low molecular mass fructo-oligosaccharides, possibly resulting in fewer side effects such as flatulence.

The mixture is composed in such a way that the size distribution of the molecules is similar to that of human milk oligosaccharides, therefore containing 90% of the low molecular mass galacto-oligosaccharides and 10% of the high molecular mass fructo-oligosaccharides. This combination promotes beneficial intestinal bacteria in a synergistic way so that a maximum number of different species, especially bifidobacteria and lactobacilli, can grow.
The prebiotic effects of both compounds have been shown in several human studies, but to our knowledge they have never been used in combination. In this study, the effect on the faecal microflora of supplementing a preterm formula with such an oligosaccharide mixture, with particular respect to bifidobacteria, was investigated in preterm infants.

PATIENTS AND METHODS

Preterm infants with a maximum gestational age of 32 weeks according to Dubowitz and Dubowitz admitted to the neonatal intensive care unit of the Hospital Mangiagalli, Milan, were eligible for the study. The study protocol was approved by the ethical committee of the hospital, and informed parental consent was obtained for each infant before enrolment in the study. For all infants, enteral nutrition was started with pasteurised mother’s milk. When a volume of 80 ml/kg/day was tolerated, the milk was supplemented with a commercially available human milk fortifier. When the neonatologist in charge decided to start formula feeding because the mother was no longer able to provide milk, the infants were randomly assigned to one of two formula groups. The compositions of the two formulas were, apart from the supplemented oligosaccharides, identical (Table 1). The feeding regimen was performed according to the practice of the hospital and was not influenced by the study protocol. A group fed fortified mother’s milk matched for sex and gestational and postnatal age was investigated as the reference group. Table 2 gives the most relevant clinical data of the infants studied.

In the experimental formula, a mixture of fructo-oligosaccharides and galacto-oligosaccharides was added to an otherwise standard preterm formula. As it was the intention to reproduce the spectrum of molecular masses of human milk, the relation between galacto-oligosaccharides and fructo-oligosaccharides was a matter of some experiment. On the basis of our own analytical data, a mixture of 9 parts galacto-oligosaccharides and 1 part fructo-oligosaccharides was found to closely resemble the spectrum of molecular masses of the neutral oligosaccharide fraction of human milk. The concentration of the mixture in the formula was adapted to the concentration of neutral oligosaccharides in human milk—that is, 10 g/l. In the control group, a similar quantity of maltodextrins was added as placebo.

The first day of full formula feeding was defined as measurement day 1. Measurements were repeated after seven, 14, and 28 days. On each of these days, faecal flora was investigated, and stool characteristics as well as possible side effects were recorded.

Microbiological analysis of fresh stool sample was performed after suspension, homogenisation, and dilution in physiological saline solution. For analysis of bifidobacteria and lactobacilli, 1 ml of the diluted suspension was inoculated into 10 ml Soybean Casein Digest Agar and incubated at 37°C for five hours. The layer of Soybean Casein Digest Agar was then overlaid with 10 ml Rogosa Agar. After microaerophilic incubation for two days at 37°C, single colonies were counted and identified on the basis of their morphology and biochemical reactions as described previously. The faecal samples were also analysed for Bacteroides, Clostridium species, Escherichia coli, Enterobacter, Citrobacter, Proteus, Klebsiella, and Candida.

The oligosaccharides were analysed by matrix assisted laser desorption/ionisation mass spectrometry (MALDI-MS) as described previously. For each spectrum, a sum of 50 single spectra was recorded in linear positive ion mode (Voyager DE-STR; Applied Biosystems, Langen, Germany).

Stool characteristics were evaluated on the basis of a questionnaire about frequency and consistency (score 1–5: 1 = watery; 2 = soft; 3 = seedy; 4 = formed; 5 = hard). The consistency of each stool of the respective day was recorded, and the mean of all scores was used to characterise the stool consistency of the respective day.

In addition, the incidence of crying (score 1–3: 1 = seldom; 2 = normal; 3 = often), regurgitation (score 1–3: 1 = none; 2 = once or twice; 3 = more than twice), and vomiting (score 1–3: 1 = none; 2 = once; 3 = more than once) was recorded on the basis of the nurse’s report.

For all infants, body weight was measured on each measurement day using a balance with an accuracy of ± 5 g. The crown-heel length was measured at the start and end of each feeding period using a special board for newborn infants with an accuracy of ± 1 mm.

Statistical analysis

All data are given as means (SD). An overall group effect on a measured variable was evaluated by one way analysis of variance. If significant, this was followed by Scheffé post hoc tests for single group comparisons. All tests were performed at α = 0.05.

### Table 1

<table>
<thead>
<tr>
<th>Composition per 100 ml of the two formulas studied</th>
<th>Formula without oligosaccharides</th>
<th>Formula with oligosaccharides</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fat (g)</td>
<td>4.4</td>
<td>4.4</td>
</tr>
<tr>
<td>Carbohydrates (g)</td>
<td>7.8</td>
<td>7.8</td>
</tr>
<tr>
<td>Lactose (g)</td>
<td>6.0</td>
<td>6.0</td>
</tr>
<tr>
<td>Maltodextrins (g)</td>
<td>1.8</td>
<td>0.8</td>
</tr>
<tr>
<td>Oligosaccharides (g)</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Protein (g)</td>
<td>0.35</td>
<td>0.35</td>
</tr>
<tr>
<td>Succinate (g)</td>
<td>235–255</td>
<td>235–255</td>
</tr>
<tr>
<td>Energy content (kJ)</td>
<td>334</td>
<td>334</td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th>Clinical characteristics of the study population</th>
<th>Control formula without OS</th>
<th>OS Formula</th>
<th>Human milk with OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (M/F)</td>
<td>15 (8/7)</td>
<td>15 (7/8)</td>
<td>12 (7/5)</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>31.2 (0.6)</td>
<td>31.5 (0.5)</td>
<td>31.4 (0.9)</td>
</tr>
<tr>
<td>Weight at birth (g)</td>
<td>1585 (241)</td>
<td>1600 (228)</td>
<td>1601 (321)</td>
</tr>
<tr>
<td>Length at birth (cm)</td>
<td>41.4 (2.0)</td>
<td>41.4 (1.9)</td>
<td>41.6 (2.9)</td>
</tr>
<tr>
<td>Head circumference at birth (cm)</td>
<td>29.6 (1.8)</td>
<td>29.9 (1.2)</td>
<td>29.9 (1.9)</td>
</tr>
<tr>
<td>Age at study entry (days)</td>
<td>8.5 (1.8)</td>
<td>8.3 (3.0)</td>
<td>7.9 (2.0)</td>
</tr>
<tr>
<td>Feeding volume (ml/kg/day)</td>
<td>175.6 (19.5)</td>
<td>171.5 (19.8)</td>
<td>186.7 (20.3)</td>
</tr>
<tr>
<td>Weight gain during study period (g/day)</td>
<td>29.8 (4.1)</td>
<td>29.8 (4.0)</td>
<td>29.7 (3.3)</td>
</tr>
<tr>
<td>Length gain during study period (cm/week)</td>
<td>0.98 (0.05)</td>
<td>0.99 (0.05)</td>
<td>1.01 (0.04)</td>
</tr>
</tbody>
</table>

Values are mean (SD). OS, Oligosaccharides.
level of 5%. \( p < 0.05 \) was considered significant. StatView 5.0 (SAS Institute Inc) was used for the analyses.

**RESULTS**

The molecular mass distribution of the mixture containing 90% galacto-oligosaccharides and 10% fructo-oligosaccharides as measured by MALDI-MS is similar to that found in the neutral oligosaccharide fraction of human milk (data not shown).

Bifidobacteria were detectable on the first measurement day in all faecal samples. There was no difference between the two formula groups, and both were in the range of the reference group. During the study period, the number of faecal bifidobacteria increased significantly with time in both groups receiving formula (\( p < 0.05 \)), but this increase was only marginal in the group fed the control formula (fig 1). After the 28 day feeding period, the number of bifidobacteria in the group fed the oligosaccharide supplemented formula was in the upper range of the reference group whereas the number in the control group fed the formula supplemented with the placebo was in the lower range. This difference between the two groups receiving formula was highly significant (\( p = 0.0008 \)) (fig 1).

Lactobaccilli were also detectable in all infants at the study entry. There was a significant increase in all groups during the course of the study period but there was no significant effect of the diet (data not shown). Neither was there a significant effect of the oligosaccharide supplement on the counts of *Bacteroides*, *Clostridium* species, *E coli*, *Enterobacter*, *Citrobacter*, Proteus, *Klebsiella*, and *Candida*.

Mean stool frequency increased slightly in the reference group fed mother’s milk, remained fairly constant in the group fed the oligosaccharide supplemented formula, and gradually decreased in the placebo group (fig 2). At day 28, the highest frequency was observed in the group fed mother’s milk (2.75 (0.8)), which was significantly higher than in the group fed the unsupplemented formula (1.33 (0.6); \( p < 0.0001 \)) and tended to be higher, but not significantly so, than in the group fed the oligosaccharide supplemented formula (2.20 (0.8); \( p = 0.1543 \)).

The stool consistency was also influenced by the diet (fig 2). In the group fed the unsupplemented formula, the score increased during the study period and reached the highest level at the end of the study period. On day 28, the hardest stools were observed in the group fed the unsupplemented formula (score 3.55 (0.8)); they were significantly harder than in the group fed the oligosaccharide supplemented formula (score 2.74 (0.7); \( p = 0.0102 \)) and in the reference group (score 2.33 (0.6); \( p = 0.0003 \)).

There was no effect of the different diets on the incidence of crying, regurgitation, or vomiting (data not shown). Weight gain and length gain was similar in all the groups (table 2).

**DISCUSSION**

The prebiotic oligosaccharide mixture used in the study was designed to stimulate growth of bifidobacteria. The data show that supplementation of a standard preterm milk formula with this mixture can significantly stimulate bifidobacterial growth, indicating a bifidogenic effect of the oligosaccharide supplement. In many studies on preterm infants, a delay in the establishment of a bifidogenic flora has been observed. In this study, the first effect of the supplementation on the
number of faecal bifidobacteria was already observed after 14
days, which underlines the bifidogenic potency of the supple-
ment. However, the effect of the supplement on the number of
bifidobacteria was more pronounced after 28 days.

A prerequisite for a bifidogenic effect of a dietary ingredient
is its resistance to digestion during passage through the small
intestine. Even though the digestibility of the supplemented
oligosaccharides was not measured in this study, the clear
bifidogenic effect indicates that their absorption was as low as
found for those in human milk.7

The increase in the number of faecal bifidobacteria was
accompanied by increased stool frequency and a significant
change towards softer stools. Increased frequency and softer
stool consistency is an effect of the supplementation that is
of practical importance because hard stools and obstipation
are common problems that limit the tolerance of preterm infants
to enteral feeding.12 Only 10 g/l of the studied mixture or pla-
cebo was added to the formula, which increases the osmolar-
ity (about 5 mOsmol/l) only slightly. Thus, the effect of the
supplementation on osmolarity cannot explain the different
effects on the stool characteristics, which are probably
influenced by changes in intestinal flora; this is in line
with many studies.

A bifidogenic effect of galacto-oligosaccharides16 17 and
fructo-oligosaccharides11 17 it has previously been shown. In
this study, the strong bifidogenic effect may be explained by
a synergistic effect of galacto- and fructo-oligosaccharides—for
example, by promoting different strains of bifidobacteria—
or, as indicated by in vitro studies, by providing
prebiotic substrate to more distal regions of the colon
because of the slower rate of fermentation of the high
molecular mass inulin fractions.13 However, as the galacto-
and fructo-oligosaccharides were not studied independently,
we cannot comment on the individual contributions of the two
oligosaccharides to the observed effects.

The study was conducted in healthy preterm infants who
tolerated complete enteral nutrition and were not receiving
antibiotic treatment—that is, a very selected population.
In addition, enteral nutrition in all infants started with mother’s
milk for several days, which may have influenced the intesti-
nal colonisation at study entry. In fact, bifidobacteria were
detected in all infants on the first day of measurement. There-
fore, the study cannot answer whether such a bifidogenic effect
would be observed if intestinal colonisation were severely
compromised—for example, after intensive antibiotic treat-
ment.

Studies in adults indicate that dietary fructo-
oligosaccharides may lead to side effects, in particular
flatulence. In a study using fructo-oligosaccharides during
infancy with an intake of up to 3 g/day, however, no such
effects were observed.14 In the present study also, in which
only 0.3 g fructo-oligosaccharides were ingested a day, no side
effects occurred.

The quantity of oligosaccharide supplement used was 10 g/l
to resemble the amount of neutral oligosaccharides found
in human milk.12 The strong and rapid effect on the bifidus flora
and stool characteristics suggests that a lower dose may have
been sufficient to achieve positive effects on the intestine. This
requires further investigation.

In summary, supplementation of a preterm formula with a
mixture of galacto- and fructo-oligosaccharides stimulates
growth of bifidobacteria and results in stool frequency and
consistency similar to those found in preterm infants fed
human milk. Thus prebiotic mixtures such as that studied
here may help to improve intestinal tolerance to enteral feed-
ing. Further studies on the optimal relation between the
different compounds and the dose of the mixture are
necessary.

ACKNOWLEDGEMENTS
The study was supported by a grant from Numico Research Germany.
We thank Mrs D Krämer and Mrs A Knossmann for performing a lit-
erature search, and Mr M Mank for performing the MALDI-MS
analyses.

Authors’ affiliations
G Boehm, J Jelinek, B Stahl, Numico Research Germany,
Friedrichsdorf, Germany
M Lidestri, A Marinì, Division of Neonatology, University of Milan,
Milan, Italy
P Casseta, F Negretti, Institute of Pharmacology, University of Milan

REFERENCES
1 Orrhage K, Nord CE. Factors controlling the bacterial colonization of
the intestine in breast fed infants. Acta Paediatr 1999;(suppl
2 Sakata H, Yoshioka H, Fujita K. Development of the intestinal flora in
very low birth weight infants: comparison to normal full-term newborns.
3 Gewolski IH, Schwabke RS, Vicki LE, et al. Stool microflora in extremely
low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1999;
80:F167–73.
colonisation in the maturation of humoral immunity in early infancy:
a prospective follow up study of healthy infants aged 0–6 months. Arch
5 Fooks IJ, Fuller R, Gibson GR. Prebiotics, probiotics and human gut
6 Gibson GR, Roberfroid MB. Dietary modulation of the human colonic
microbiota: introducing the concept of prebiotics. J Nutr
7 Walker WA, Duffy, LC. Diet and bacterial colonization: role of
8 Newburg DS. Oligosaccharides in human milk and bacterial
9 Kunz C, Rudloff S. Biological functions of oligosaccharides in human
10 Engler MB, Stahl B, Finke B, et al. Human milk oligosaccharides are
resistant to enzymatic hydrolysis in the upper gastrointestinal tract.
11 Thurl S, Muller-Werner B, Sawatzki G. Quantification of individual
oligosaccharide compounds from human milk using high-pH
12 Stahl B, Thurl S, Zeng J, et al. Oligosaccharides from human milk as
revealed by matrix assisted laser desorption/ionization mass
oligosaccharides from human milk by liquid chromatography and
14 Zorrate S, Lopez-Leiva MH. Oligosaccharide formation during enzymatic
lactose hydrolysis: a literature review. Journal of Food Protection
15 Roberfroid MB, Van Loo JAE, Gibson GR. The bifidogenic nature of
16 Dombra M, Yamamoto H, Nakajima H. Production, health benefits and
applications of galacto-oligosaccharides. In: Yalpani M, ed. New
technologies for healthy foods and nutraceuticals. Shrewsbury, USA:
17 Roberfroid MB. Health benefits of non-digestible oligosaccharides. In:
Kritischeswsky M, Bonfield G, eds. Dietary fiber in health and disease.
18 Gibson RG, Roberfroid MB. Dietary modulation of the human colonic
microbiota: introducing the concept of probiotics. J Nutr
galacto-oligosaccharides increases fecal bifidobacteria and modifies
colonic fermentation metabolism in healthy humans. J Nutr
20 Dubowitz LM, Dubowitz V. Clinical assessment for gestational age
21 Casetto P, Negrelli F, Marinì A. Repeated oral treatments with
Bifidobacterium bifidum and Bifidobacterium lactis HN019 influence on
the intestinal immunity and colonization. Development and Physiopathology
by matrix assisted laser desorption/ionization mass spectrometry. Anal
Biochem 1997;246:195–204.
23 Williams AF. Role of feeding in the pathogenesis of necrotizing
24 Guesry PR, Bodansky H, Tomáz E, et al. Effect of 3 doses of
fructo-oligosaccharides in infants. J Pediatr Gastroenterol Nutr